drugset / Trial / NCT00817219

Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris

NCT00817219

Phase 2 Completed 33 enrolled LEO Pharma
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of 4 weeks of TACLONEX ointment in adolescent patients with psoriasis vulgaris.

Timeline

Start
2009-07
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcipotriol Small molecule Topical
Subject betamethasone dipropionate Small molecule Topical

Indications